多西紫杉醇联合希罗达治疗蒽环类失败复发晚期乳腺癌的疗效观察

目的观察多西紫杉醇联合希罗达治疗蒽环类耐药晚期乳腺癌的疗效和不良反应。方法 20例蒽环类耐药复发晚期乳腺癌患者采用多西紫杉醇（65 mg/m2静滴d1）联合希罗达（900～1 000 mg/m2口服,每日2次,d1～d14）治疗,每3周为1周期,2周期后按WHO标准评价疗效,同时观察不良反应。结果20例患者均可评价疗效和不良反应,其中完全缓解CR4例,部分缓解PR8例,疾病稳定SD5例,疾病进展PD3例,有效率（CR＋PR）60.0%,获益率85.0%,中位疾病进展时间为9.0个月,1年生存率82.0%,主要不良反应为血液学毒性和消化道反应及疲乏,以1～2级为主,均可耐受。结论多西紫杉醇联合希罗达治疗蒽环类耐药失败复发晚期乳腺癌有效,其不良反应能够耐受。

Docetaxel Combined With Xeloda For Anthracycline-resistant Advanced Breast Cancer

Objective To observe the efficacy and toxicity of docetaxel combined with Xeloda for anthracycline resistant advanced breast cancer.Methods Twenty patients with advanced breast cancer were treated with doceted（65 mg/m2 iv d1）and xelod（900～1 000 mg/m2,oral administration,d1～d14）.Three weeks was a cycle.The efficacy and toxicity were evaluated by WHO standards after 2-cycle treatment.Results The efficacy and toxicity could be evaluated in the 20 patients with4 of CR,8 of PR,5 of SP and3 of PD.The response rate was 60.0%and clinical benefit rate was 85.0%.The median time to progress was 9 months and 1-year survival rate was 82.0%.The most common toxicities were bema to logical and digestive toxic reactions,mainly 1～2 degree,and could be well-tolerated.Conclusion The efficacy of docetaxel combined with capecitabine for anthracycline resistant advanced breast cancer recurrence of failure,its adverse reactions can be tolerated.